Objective To observe the clinical efficacy and safety of the Shajiganruji(SJ),in treating the irritable bowel syndrome (DIBS).Methods Randomized controlled open clinical trial design was adopted,45 patients were randomly divided into two groups, SJ and pinaverium bromide (PVB) were given as treated and control agent respectively. IBS scoring system (BSS),defecation state questionnaire (DSQ)were used to record the changes of the patients main symptoms before and after treatment. Results The total effective rate of SJ group was 85.9%,while that of PVB was 73.3%.CJT was superior in efficacy to that of PVB in improving stool quality, reducing defecation episodes of diarrheic patients, alleviating tenesmus symptoms, decreasing bellyache days and ameliorating abdominal distention. Any drug-related adverse reaction was not seen. Conclusion The efficacy of SJ in treating IBS is definite and without any toxic and adverse effects

objective for the sake of valid treatment method of the study migraine. Method adoption western medicine west compares to work properly to take orally the treatment. Result 50 cure 13 in the examples, have 26.0%;Show 26 of effect, have 52.0%;Turn for the better 8, have 16.0%;Invalid 3, have 6.0%, total and efficient 94.0%.

目的探讨运用中西医结合方法治疗病毒性心肌炎的临床效果.方法随机抽取病毒性心肌炎病人147例,分为两组.治疗观察组84例,在采用西药治疗的基础上加用中药治疗.对照组63例病人单纯采用西药治疗.结果对照组病人63例,治愈42例,好转21例,治愈率为66.7%;平均住院时间为28.0d.治疗观察组84例病人,临床治愈76例,好转6例,有效2例,治愈率为90.48%,平均住院天数21.0 d.两组病人对照结果(p＜0.05)差异明显.结论本人认为病毒性心肌炎采用中西医结合治疗效果优于单纯使用西药治疗,且疗程短、治愈率高,值得临床推广应用.

Objective To observe the effect of Xuefuzhuyu Oral Solution(XFOS) in treating coronary heart disease with angina pectoris. Methods Eighty patients were randomly divided into two groups. They were treated with XFOS group and isosorbide dinitrate combined aspirin(control group) respectively for 4 weeks and observed by single blind method. Results The total effective rate in relieving angina in the XFOS group and the control group was 92.5% and 75% respectively , that in improving ECG changes was 65% and 40% respectively, the difference of the two parameters between the two groups was significant, all P<0.05.Levels of total cholesterol(TC) and low density lipoprotein-cholesterol(LDL-C)were lowered in the XFOS group while LDL-C was increased in the control group. Conclusion XLOS has better effect in improving angina pectoris, ischemic changes in ECG, it could also reduce the serum TC and LDL-C level and decrease the arteriosclerosis index.

Objective Probe into the relation between food and asthma,include the characterstics of the food species and clinic performance.Methods Carry on the food skin particularity allergy's experiment to 36 asthma sufferers.Results All have one item or more positive reaction of skins experiment and part responds were strong reaction.Check the control liquid is negative.Among the sensityzing food,the fresh water fish share the first,the next in order for foods,such as sea fish,shrimp,seasame and red small bean...etc..Conclusion Food allergy is an important inducing factor of the bronchus asthma,and the asthma can be a kind of symptom of the food allergy,it is essential know that on the clinic,in order to make diagnosis and give treatment in time.

Objective To observe the effect of irbesartan in treating patients with congestive heart failure(CHF).Methods Fifty-eight patients with CHF were randomly divided into irbesartan treated group and routine treatment group.The former was given irbesartan (AngiotensinII receptor antagonist)75～150mg orally once a day for 46 weeks besides routine treatment.The changes of heart rate (HR),blood pressure(BP),left ventricular end diastolic diameter (LVEDD),left ventric-ular ejection fraction (LVEF) and cardiac function (NYHA) were observed.Results After 4～6 weeks therapy,HR,BP,cardiothoracic ratio and LVEDD all decreased significantly(P<0.05,<0.01);LVEF increased (P<0.01);car-diac function (NYHA)improved 1- 2grade.Irbesartan had few adverse effects and patients′tolerance was perfect.Conclusion The effect of irbesartan in treating patients with congestive heart failure is satisfing.It has few side effect.It appears to be a new therapy for patients with chronic heart failure.

目的探讨超敏 C-反应蛋白(hs-CRP)和总胆固醇与高密度脂蛋白胆固醇比值(TC/HDL-C)联合检测对冠状动脉粥样硬化性心脏病(CHD)的预测价值。方法对60例 CHD 患者和30例健康对照者进行血清 hs-CRP、TC 和 HDL-C 测定,分析计算 TC/HDL-C 比值。结果 CHD 患者血清 hs-CRP 浓度和 TC/HDL-C 比值均显著高于对照组(P<0.01)。联合应用 hs-CRP 和 TC/HDL-C比值2种指标时 CHD 患者的诊断阳性率(93.3%)高于单独应用 hs-CRP(84.0%)或 TC/HDL-C(73.3%)。结论应用 hs-CRP检测和 TC 与、DL-C 比值2项指标联合检测,更有助于冠心病的早期诊断。

Objective To study the effects of integrated Liposomal prostaglandin E1 (Lipo PGE1) and benazepril on early diabetic nephropathy(DN) and clinical DN.Methods 60 patients of type 2 diabetic patients with DN were randomly divided into control group (benazepril) and treated group (benazepril+Lipo PGE1).UARE,Scr and BUN figures were compared between two groups before treatment and eight weeks after treatment.Results UAER had been decreased significantly in both groups(P0.05,P0.01),and more significantly in treated group than in control group(P0.05),Scr had been decreased significantly in treated group(P0.01).while no significantly decrease of Scr had been found in control group during the follow-up (P0.05).Furtheremore,no significant decrease of BUN, FBG,MPA,TC and TG had been found in both groups.Conclusion Integrated Lipo PGE1 and benazepril can ameliorate protenuria and improve renalfunction of the patients with early DN ang clinical DN of normal renal function.